Biosynex (ALBIO) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.160x

Based on the latest financial reports, Biosynex (ALBIO) has a cash flow conversion efficiency ratio of -0.160x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.07 Million ≈ $-8.26 Million USD) by net assets (€44.31 Million ≈ $51.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Biosynex - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Biosynex's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALBIO current and long-term liabilities for a breakdown of total debt and financial obligations.

Biosynex Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biosynex ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Kingsmen C.M.T.I. Public Company Limited BK:K	0.102x
Hank Payments Corp V:HANK	0.083x
Laser Photonics Corporation Common Stock NASDAQ:LASE	0.186x
Hanchang KO:005110	0.818x
Currys PLC LSE:CURY	0.059x
Clean Seas Seafood Limited F:C7S	-0.016x
Ovanti Ltd AU:OVT	-0.245x
NexturnBioscience Co. Ltd KQ:089140	0.019x

Annual Cash Flow Conversion Efficiency for Biosynex (2008–2024)

The table below shows the annual cash flow conversion efficiency of Biosynex from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Biosynex (ALBIO) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€80.50 Million ≈ $94.11 Million	€-10.12 Million ≈ $-11.83 Million	-0.126x	-61.91%
2023-12-31	€124.31 Million ≈ $145.34 Million	€-9.65 Million ≈ $-11.29 Million	-0.078x	-361.86%
2022-12-31	€166.76 Million ≈ $194.96 Million	€4.95 Million ≈ $5.78 Million	0.030x	-95.47%
2021-12-31	€167.81 Million ≈ $196.18 Million	€109.83 Million ≈ $128.41 Million	0.655x	+37.14%
2020-12-31	€66.29 Million ≈ $77.50 Million	€31.64 Million ≈ $36.99 Million	0.477x	+1213.25%
2019-12-31	€30.38 Million ≈ $35.52 Million	€1.10 Million ≈ $1.29 Million	0.036x	+127.67%
2018-12-31	€29.26 Million ≈ $34.21 Million	€467.12K ≈ $546.11K	0.016x	-4.82%
2017-12-31	€28.91 Million ≈ $33.80 Million	€484.82K ≈ $566.81K	0.017x	-16.59%
2016-12-31	€24.36 Million ≈ $28.48 Million	€489.91K ≈ $572.75K	0.020x	-7.96%
2015-12-31	€21.13 Million ≈ $24.70 Million	€461.66K ≈ $539.73K	0.022x	+110.31%
2009-12-31	€-341.55K ≈ $-399.30K	€72.40K ≈ $84.65K	-0.212x	-117.67%
2008-12-31	€-153.74K ≈ $-179.73K	€-184.44K ≈ $-215.63K	1.200x	--

About Biosynex

PA:ALBIO France Medical Devices

Market Cap

$16.81 Million

€14.38 Million EUR

Market Cap Rank

#25694 Global

#426 in France

Share Price

€0.78

Change (1 day)

-2.50%

52-Week Range

€0.48 - €1.51

All Time High

€25.28